{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:00:17Z","timestamp":1782709217716,"version":"3.54.5"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Shanxi Province Natural Science Foundation","doi-asserted-by":"publisher","award":["202403021221261"],"award-info":[{"award-number":["202403021221261"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Shanxi Province Natural Science Foundation","doi-asserted-by":"publisher","award":["202303021222147"],"award-info":[{"award-number":["202303021222147"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC3402800"],"award-info":[{"award-number":["2023YFC3402800"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32301200"],"award-info":[{"award-number":["32301200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071987"],"award-info":[{"award-number":["82071987"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82120108016"],"award-info":[{"award-number":["82120108016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071997"],"award-info":[{"award-number":["82071997"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008549","name":"Shanxi Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113680","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:57:51Z","timestamp":1743739071000},"page":"113680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Innovative nanomedicine approaches for the management of nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"382","author":[{"given":"Limeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113680_bb0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0025","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.113680_bb0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jconrel.2023.09.040","article-title":"Nonalcoholic fatty liver disease: current therapies and future perspectives in drug delivery","volume":"363","author":"Domingues","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113680_bb0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.jconrel.2025.113680_bb0040","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.jconrel.2025.113680_bb0045","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.113680_bb0050","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.113680_bb0055","first-page":"851","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis, lancet","volume":"7","author":"Riazi","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0060","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 To 2018: a systematic review and meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.113680_bb0065","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2022.0401","article-title":"Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis","volume":"29","author":"Shi","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0090","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","article-title":"Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults","volume":"20","author":"Liu","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0095","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/17474124.2021.1914587","article-title":"Liver-spleen axis in nonalcoholic fatty liver disease","volume":"15","author":"Tarantino","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.freeradbiomed.2013.08.174","article-title":"Free radical biology for medicine: learning from nonalcoholic fatty liver disease","volume":"65","author":"Serviddio","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0080","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1053\/j.gastro.2022.01.058","article-title":"Nonalcoholic fatty liver disease and the gut-liver axis: exploring an undernutrition perspective","volume":"162","author":"Bauer","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.113680_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0130","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.cgh.2015.07.029","article-title":"Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes","volume":"13","author":"Ahmed","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2025.113680_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0145","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Lin","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0150","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator\u2212activated receptor\u2212\u03b1 and \u2212\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.113680_bb0155","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181304","article-title":"Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2025.113680_bb0160","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.jconrel.2025.113680_bb0165","first-page":"1618","article-title":"Saxagliptin regulates M1\/M2 macrophage polarization via CaMKK\u03b2\/AMPK pathway to attenuate NAFLD","volume":"503","author":"Yang","year":"2018","journal-title":"BBRC"},{"key":"10.1016\/j.jconrel.2025.113680_bb0170","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.113680_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119388","article-title":"Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1","author":"Xie","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2025.113680_bb0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0115","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.jconrel.2025.113680_bb0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.jconrel.2025.113680_bb0190","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: in NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jconrel.2025.113680_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101187","article-title":"FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice","volume":"49","author":"Lee","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113680_bb0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"C, insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0215","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0220","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jconrel.2025.113680_bb0225","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"J, a randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113680_bb0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease","volume":"66","author":"Rotman","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2025.113680_bb0235","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jconrel.2024.03.055","article-title":"All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment","volume":"369","author":"Ding","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113680_bb0240","first-page":"364","article-title":"Therapeutic targeting of liver inflammation and fibrosis by nanomedicine","volume":"3","author":"Bartneck","year":"2014","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.jconrel.2025.113680_bb0245","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jconrel.2022.06.029","article-title":"Nanodisc delivery of liver X receptor agonist for the treatment of diabetic nephropathy","volume":"348","author":"He","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113680_bb0250","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cmet.2019.11.013","article-title":"Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis","volume":"31","author":"Cai","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2025.113680_bb0255","first-page":"273","article-title":"M2 macrophage-derived exosomes promote diabetic fracture healing by acting as an immunomodulator","volume":"28","author":"Wang","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2025.113680_bb0260","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.30645","article-title":"MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes","volume":"70","author":"He","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl_1","key":"10.1016\/j.jconrel.2025.113680_bb0265","doi-asserted-by":"crossref","first-page":"A478","DOI":"10.1161\/atvb.43.suppl_1.478","article-title":"Aberrant glycogen synthase kinase 3 activation in liver sinusoidal endothelial cells enhances liver inflammation in nonalcoholic steatohepatitis","volume":"43","author":"Ibrahim","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113680_bb0270","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acsnano.3c06107","article-title":"Antioxidative hyaluronic acid-bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy","volume":"18","author":"Shinn","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113680_bb0275","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jconrel.2021.11.039","article-title":"Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH","volume":"341","author":"Maeda","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113680_bb0280","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12951-021-00979-1","article-title":"Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice","volume":"19","author":"Chen","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0285","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s42255-023-00896-7","article-title":"Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice","volume":"5","author":"Yao","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.jconrel.2025.113680_bb0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","article-title":"The landscape of small-molecule prodrugs","volume":"23","author":"Fralish","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113680_bb0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2019.06.023","article-title":"The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease","volume":"307","author":"Teng","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113680_bb0290","article-title":"Hepatic-accumulated obeticholic acid and atorvastatin self-assembled nanocrystals potentiate ameliorative effects in treatment of metabolic-associated fatty liver disease","volume":"11","author":"Lu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.113680_bb0305","article-title":"The dual-target nanoparticles with ROS sensitivity inhibit the hedgehog signaling pathway and decrease oxidative stress in activated hepatic stellate cells to alleviate liver fibrosis","volume":"2404658","author":"Zhang","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113680_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122047","article-title":"Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis","volume":"295","author":"Shashni","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113680_bb0315","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.1038\/s41467-024-51571-8","article-title":"RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment","volume":"15","author":"Shan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113680_bb0320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113680_bb0325","article-title":"Incorporation of glycyrrhizic acid and polyene phosphatidylcholine in lipid nanoparticles ameliorates acute liver injury via delivering p65 siRNA","volume":"48","author":"Yin","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.113680_bb0330","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acsnano.3c03217","article-title":"Nanoparticle-mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113680_bb0335","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cell.2020.08.009","article-title":"Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output","volume":"183","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2025.113680_bb0340","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1038\/s41467-023-39423-3","article-title":"Antioxidant hepatic lipid metabolism can be promoted by orally administered inorganic nanoparticles","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113680_bb0345","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.apsb.2024.02.017","article-title":"A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment","volume":"14","author":"Fu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.113680_bb0350","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.113680_bb0355","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.31658","article-title":"Myeloid cell-specific IL-6 signaling promotes miR-223-enriched exosome production to attenuate NAFLD-associated fibrosis","volume":"74","author":"Hou","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.113680_bb0360","article-title":"Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis","volume":"5","author":"Yang","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.jconrel.2025.113680_bb0365","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s13577-021-00593-1","article-title":"Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression","volume":"34","author":"Cheng","year":"2021","journal-title":"Hum. Cell"},{"key":"10.1016\/j.jconrel.2025.113680_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9435","article-title":"Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases","volume":"8","author":"Wan","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113680_bb0375","first-page":"53","article-title":"Plant-derived exosome-like nanoparticles and their therapeutic activities, Asian","volume":"17","author":"Kim","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113680_bb0380","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41401-021-00681-w","article-title":"Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress","volume":"43","author":"Zhao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2025.113680_bb0385","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"154-155","author":"B\u00f6ttger","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113680_bb0390","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41467-022-30813-7","article-title":"Efficient aqueous remote loading of peptides in poly(lactic-co-glycolic acid)","volume":"13","author":"Giles","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113680_bb0395","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jpha.2023.06.001","article-title":"Applications and safety of gold nanoparticles as therapeutic devices in clinical trials","volume":"13","author":"Yao","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jconrel.2025.113680_bb0400","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jhep.2020.04.044","article-title":"Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis","volume":"73","author":"Gao","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0405","doi-asserted-by":"crossref","first-page":"20825","DOI":"10.1021\/acsnano.3c05853","article-title":"Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113680_bb0410","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s11658-024-00655-w","article-title":"Early and late phases of liver sinusoidal endothelial cell (LSEC) defenestration in mouse model of systemic inflammation","volume":"29","author":"Czyzynska-Cichon","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.jconrel.2025.113680_bb0415","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202003721","article-title":"Adipocyte fatty acid binding protein promotes the onset and progression of liver fibrosis via mediating the crosstalk between liver sinusoidal endothelial cells and hepatic stellate cells","volume":"8","author":"Wu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.113680_bb0420","article-title":"Nanodrug delivery: strategies to circumvent nanoparticle trafficking by Kupffer cells in the liver","volume":"86","author":"Ezhilarasan","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-8977-4-10","article-title":"Kupffer cells are central in the removal of nanoparticles from the organism","volume":"4","author":"Sadauskas","year":"2007","journal-title":"Part Fibre Toxicol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0430","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113680_bb0435","doi-asserted-by":"crossref","first-page":"14029","DOI":"10.1021\/acsnano.2c03858","article-title":"Sequential nano-penetrators of capillarized liver sinusoids and extracellular matrix barriers for liver fibrosis therapy","volume":"16","author":"Zhang","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113680_bb0440","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.actbio.2023.12.027","article-title":"Wang, B, collagenase type I and probucol-loaded nanoparticles penetrate the extracellular matrix to target hepatic stellate cells for hepatic fibrosis therapy","volume":"175","author":"Wang","year":"2024","journal-title":"Acta Biomater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:05:50Z","timestamp":1777871150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":85,"alternative-id":["S0168365925003001"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113680","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative nanomedicine approaches for the management of nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113680"}}